<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04778878</url>
  </required_header>
  <id_info>
    <org_study_id>48/2019</org_study_id>
    <nct_id>NCT04778878</nct_id>
  </id_info>
  <brief_title>Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device</brief_title>
  <acronym>APPS</acronym>
  <official_title>Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in&#xD;
      early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine,&#xD;
      oxaliplatin or docetaxel) as a part of their chemotherapy regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Nerve conductivity</measure>
    <time_frame>6 weeks</time_frame>
    <description>Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve conductivity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve conductivity</measure>
    <time_frame>18 weeks</time_frame>
    <description>Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve conductivity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Nerve conductivity of n. medianus and ulnaris by Mediracer® NCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathy related pain</measure>
    <time_frame>6 weeks</time_frame>
    <description>Neuropathy related pain according to NPSI-assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathy related pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Neuropathy related pain according to NPSI-assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathy related pain</measure>
    <time_frame>18 weeks</time_frame>
    <description>Neuropathy related pain according to NPSI-assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neuropathy related pain</measure>
    <time_frame>24 weeks</time_frame>
    <description>Neuropathy related pain according to NPSI-assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy induced peripheral neuropathy (CIPN)</measure>
    <time_frame>6 weeks</time_frame>
    <description>CIPN assessed by EORTC QLQ-CIPN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy induced peripheral neuropathy (CIPN)</measure>
    <time_frame>12 weeks</time_frame>
    <description>CIPN assessed by EORTC QLQ-CIPN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy induced peripheral neuropathy (CIPN)</measure>
    <time_frame>18 weeks</time_frame>
    <description>CIPN assessed by EORTC QLQ-CIPN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chemotherapy induced peripheral neuropathy (CIPN)</measure>
    <time_frame>24 weeks</time_frame>
    <description>CIPN assessed by EORTC QLQ-CIPN20 questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CIPN by CTCAE</measure>
    <time_frame>6 weeks</time_frame>
    <description>Frequency of CIPN by CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CIPN by CTCAE</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of CIPN by CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CIPN by CTCAE</measure>
    <time_frame>18 weeks</time_frame>
    <description>Frequency of CIPN by CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of CIPN by CTCAE</measure>
    <time_frame>24 weeks</time_frame>
    <description>Frequency of CIPN by CTCAE</description>
  </primary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mediracer® NCS</intervention_name>
    <description>A point-of-care, hand-held nerve conduction device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving neurotoxic chemotherapy (oxaliplatin, vincristine, or docetaxel) as&#xD;
        cancer treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Planned initiation of oxaliplatin-, vincristine- or docetaxel-containing chemotherapy&#xD;
             regimen [FOLFOX, XELOX, (R)-CHOP/CHOEP/CVOP, docetaxel, docetaxel-doxorubicin]&#xD;
&#xD;
          3. Age &gt;18y&#xD;
&#xD;
          4. ECOG 0-2&#xD;
&#xD;
          5. Patient compliant with the study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient not fit/suitable for aforementioned chemotherapy regimen at baseline&#xD;
&#xD;
          2. Any prior postoperative or post-traumatic conditions affecting the sensory and/or&#xD;
             motoric peripheral nerves&#xD;
&#xD;
          3. General vulnerability affecting the participation in the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oulu University Hospital</investigator_affiliation>
    <investigator_full_name>Jussi Koivunen</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>CIPN, NCS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

